A PYMNTS Company

Japan: Takeda wins shareholder approval for US$59B Shire acquisition

By  |  December 5, 2018

Takeda Pharmaceutical has won shareholder approval to finance its £46 billion (US$58.6 billion) purchase of Shire, paving the way for Japan’s largest corporate takeover and the creation of a global drugmaker with combined revenues of US$32 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The vote on Wednesday, December 5, caps months of aggressive campaigning by Christophe Weber, Takeda’s CEO, to fend off attempts by founding family members to derail a deal that the 237-year-old group sees as pivotal to securing its place among the world’s top 10 pharmaceutical companies.

    According to the Wall Street Journal, the acquisition propels 237-year-old Takeda into the big leagues, making the combined entity the world’s eighth-largest drugmaker by sales, and reflects how Japan’s corporate titans are looking abroad to fuel growth. Together, the companies would be estimated to earn half their revenue from the US, up from the roughly one-third that Takeda makes now. Takeda also estimates annual savings would reach at least US$1.4 billion three years after the merger.

    Full Content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.